ArticleEuropean journal of neurology2026
Blood Pressure Control With Clevidipine Is Associated With Hematoma Volume Reduction in Acute Hypertensive Intracerebral Hemorrhage: A Single-Center Prospective Cohort Study.
Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIntracerebral hemorrhage (ICH) is associated with adverse functional outcomes and elevated mortality, driven by hematoma size and expansion. Timely blood pressure (BP) management may help mitigate hematoma growth. We aimed to assess the effects of clevidipine, an intravenously administered calcium-channel blocker, on hematoma volume and functional outcomes compared with standard antihypertensive therapy in hypertensive ICH patients.
methodsWe performed a prospective cohort study with a historical control group assessing serial hematoma volume measurements and clinical outcomes in acute hypertensive ICH patients treated with intravenous clevidipine (2023-2025) compared with standard antihypertensive therapy using labetalol, clonidine and/or diuretics (2020-2022; prior to clevidipine availability).
resultsSixty-four patients (cases:25; controls:39) were included. There was no difference in demographic characteristics and admission National Institutes of Health Stroke Scale (NIHSS) scores between cases and controls. Clevidipine administration resulted in effective BP control (< 140/90 mmHg) within 3.5 ± 3.2 h from treatment onset, with no hematoma expansion (0.0 vs. 7.7% in controls; p = 0.172) and significant ICH volume reduction on 24-h follow-up brain-CT (14.7% vs. 4.5% in controls; p = 0.023). A trend toward greater improvement in NIHSS scores during hospitalization and numerically lower 3-month mortality rates were observed in clevidipine group. No serious adverse events were reported in the clevidipine-treated patients. In multivariable linear regression models adjusting for potential confounders, clevidipine-use was independently associated with greater ICH-volume reduction (β = -0.16, 95% CI: -0.30, -0.02, p = 0.024).
conclusionsThe present study highlights that clevidipine represents a safe and effective option in terms of acute BP management among patients with hypertensive ICH and may limit hematoma expansion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.